Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial by Mega, JL, MD, Braunwald, E, Prof, Mohanavelu, S, MS, Burton, P, MD, Poulter, R, MB, Misselwitz, F, MD, Hricak, V, Prof, Barnathan, ES, MD, Bordes, P, MD, Witkowski, A, Prof, Markov, V, Prof, Oppenheimer, L, PhD, Gibson, CM, MD

Get full text

BAY 59‐7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose‐ranging study by TURPIE, A. G. G., FISHER, W. D., BAUER, K. A., KWONG, L. M., IRWIN, M. W., KÄLEBO, P., MISSELWITZ, F., GENT, M.

Get full text

Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement by ERIKSSON, B. I., BORRIS, L., DAHL, O. E., HAAS, S., HUISMAN, M. V., KAKKAR, A. K., MISSELWITZ, F., KÄLEBO, P.

Get full text

Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study by SCHELLONG, S. M., BEYER, J., KAKKAR, A. K., HALBRITTER, K., ERIKSSON, B. I., TURPIE, A. G. G., MISSELWITZ, F., KÄLEBO, P.

Get full text

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial by Kakkar, Ajay K, Prof, Brenner, Benjamin, Prof, Dahl, Ola E, MD, Eriksson, Bengt I, MD, Mouret, Patrick, MD, Muntz, Jim, MD, Soglian, Andrea G, MD, Pap, Ákos F, Misselwitz, Frank, MD, Haas, Sylvia, Prof

Get full text

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial by Turpie, Alexander GG, MD, Lassen, Michael R, MD, Davidson, Bruce L, MD, Bauer, Kenneth A, MD, Gent, Michael, DSc, Kwong, Louis M, MD, Cushner, Fred D, MD, Lotke, Paul A, MD, Berkowitz, Scott D, MD, Bandel, Tiemo J, MD, Benson, Alice, MS, Misselwitz, Frank, MD, Fisher, William D, MD

Get full text

Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events by BORRIS, L. C., BREINDAHL, M., LASSEN, M. R., PAP, A. F., MISSELWITZ, F.

Get full text

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular OutcoMes for People Using Anticoagulation StrategieS (COMPASS) Trial by Bosch, Jackie, MSc, PhD, Eikelboom, John W., MBBS, MSc, Connolly, Stuart J., MD, Cook Bruns, Nancy, MD, Lanius, Vivian, PhD, Yuan, Fei, MMath, Misselwitz, Frank, MD, PhD, Chen, Edmond, MD, Diaz, Rafael, MD, Alings, Marco, MD, PhD, Lonn, Eva M., MD, MSc, Widimsky, Petr, MD, DSc, Hori, Masatsugu, MD, PhD, Avezum, Alvaro, MD, PhD, Piegas, Leopoldo S., MD, Bhatt, Deepak L., MD, MPH, Branch, Kelley R.H., MD, MSc, Probstfield, Jeffrey L., MD, Liang, Yan, MD, Liu, Lisheng, MD, Zhu, Jun, MD, Maggioni, Aldo P., MD, Lopez-Jaramillo, Patricio, MD, PhD, O’Donnell, Martin, MB, PhD, Fox, Keith A.A., BSc, MBChB, Kakkar, Ajay, MBBS, PhD, BSc, MA, Parkhomenko, Alexander N., MD, PhD, Ertl, Georg, MD, Störk, Stefan, MD, PhD, Keltai, Katalin, MD, Keltai, Matyas, MD, Ryden, Lars, MD, Dagenais, Gilles R., MD, Pogosova, Nana, MD, PhD, Dans, Antonio L., MD, MSc, Lanas, Fernando, PhD, Commerford, Patrick J., MBChB, Torp-Pedersen, Christian, MD, Guzik, Tomasz J., MD, PhD, MSc, Verhamme, Peter B., MD, Vinereanu, Dragos, MD, PhD, Kim, Jae-Hyung, MD, PhD, Ha, Jong-Won, MD, PhD, Tonkin, Andrew M., MD, MBBS, Varigos, John D., BSc (Hon), Lewis, Basil S., MD, Felix, Camilo, MD, MSc, Yusoff, Khalid, MBBS, Steg, Philippe Gabriel, MD, Aboyans, Victor, MD, PhD, Metsarinne, Kaj P., MD, PhD, Anand, Sonia S., MD, PhD, Hart, Robert G., MD, Lamy, Andre, MD, MHSc, Moayyedi, Paul, BSc, MBChB, PhD, Sharma, Mukul, MD, MSc, Yusuf, Salim, MBBS,-DPhil

Get full text

Patients with AF and dementia are undertreated for their AF and cardiovascular comorbidities: results from the GARFIELD-AF registry by Virdone, S, Camm, A J, Bassand, J P, Fox, K A A, Haas, S, Verheugt, F W A, Misselwitz, F, Keltai, M, Ten Cate, H, Almahmeed, W, Ragy, H I, Himmelreich, J C L, Pieper, K, Kayani, G, Kakkar, A K

Get full text

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement by ERIKSSON, Bengt I, BORRIS, Lars C, DAHL, Ola E, HAAS, Sylvia, HUISMAN, Menno V, KAKKAR, Ajay K, MUEHLHOFER, Eva, DIERIG, Christoph, MISSELWITZ, Frank, KÄLEBO, Peter

Get full text

Impact of NOAC and VKA on outcome of patients with newly diagnosed atrial fibrillation and diabetes: a report from the GARFIELD-AF registry by Bassand, J, Virdone, S, Verheugt, F.W.A, Camm, A.J, Cools, F, Fox, K.A.A, Goldhaber, S.Z, Goto, S, Haas, S, Hacke, W, Kayani, G, Misselwitz, F, Pieper, K.S, Turpie, A.G.G, Kakkar, A.K

Get full text

Safety and efficacy of apixaban and rivaroxaban versus warfarin in real-world atrial fibrillation patients are similar to their randomized trials: insights from GARFIELD-AF registr... by Himmelreich, J.C.L, Virdone, S, Camm, A.J, Harskamp, R.E, Pieper, K.S, Fox, K.A.A, Bassand, J.-P, Fitzmaurice, D.A, Goldhaber, S.Z, Goto, S, Haas, S, Misselwitz, F, Turpie, A.G.G, Verheugt, F.W.A, Kakkar, A.K

Get full text

Comparative effectiveness of NOAC vs VKA in patients representing common clinical challenges: results from the GARFIELD-AF registry by Virdone, S, Himmelreich, J.C.L, Pieper, K.S, Camm, A.J, Bassand, J.-P, Fox, K.A.A, Fitzmaurice, D.A, Goldhaber, S.Z, Goto, S, Haas, S, Kayani, G, Misselwitz, F, Turpie, A.G.G, Verheugt, F.W.A, Kakkar, A.K

Get full text

Comparing rivaroxaban and apixaban in GARFIELD-AF according to ROCKET AF and ARISTOTLE trial selection criteria by Himmelreich, J.C.L, Virdone, S, Camm, A.J, Harskamp, R.E, Pieper, K.S, Fox, K.A.A, Bassand, J.-P, Fitzmaurice, D.A, Goldhaber, S.Z, Goto, S, Haas, S, Misselwitz, F, Turpie, A.G.G, Verheugt, F.W.A, Kakkar, A.K

Get full text

Permanent discontinuation of different anticoagulants in patients with atrial fibrillation and the impact on clinical outcome: data from the GARFIELD-AF registry by Cools, F, Johnson, D, Pieper, K.S, Camm, A.J, Bassand, J.-P, Fitzmaurice, D.A, Fox, K.A.A, Goldhaber, S.Z, Goto, S, Haas, S, Turpie, A.G.G, Verheugt, F.W.A, Misselwitz, F, Kayani, G, Kakkar, A.K

Get full text

The effect of body mass index on clinical outcomes in patients with newly diagnosed atrial fibrillation in the GARFIELD-AF registry by Camm, C.J.F, Camm, A.J, Virdone, S, Bassand, J.-P, Fitzmaurice, D.A, Fox, K.A.A, Goldhaber, S.Z, Goto, S, Haas, S, Turpie, A.G.G, Verheugt, F.W.A, Misselwitz, F, Kayani, G, Pieper, K.S, Kakkar, A.K

Get full text

Clinical outcomes of patients with newly diagnosed atrial fibrillation who refused anticoagulation: findings from the global GARFIELD-AF registry by Apenteng, P, Fitzmaurice, D.A, Virdone, S, Camm, A.J, Fox, K.A.A, Bassand, J.-P, Goldhaber, S.Z, Goto, S, Haas, S, Turpie, A.G.G, Verheugt, F.W.A, Misselwitz, F, Kayani, G, Pieper, K.S, Kakkar, A.K

Get full text

Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF by Camm, A.J, Steffel, J, Virdone, S, Bassand, J.-P, Fitzmaurice, D.A, Fox, K.A.A, Goldhaber, S.Z, Goto, S, Haas, S, Turpie, A.G.G, Verheugt, F.W.A, Misselwitz, F, Kayani, G, Pieper, K.S, Kakkar, A.K

Get full text

P3569Impact of body mass index in newly diagnosed atrial fibrillation in the GARFIELD-AF registry by Goldhaber, S.Z., Bassand, J.P., Accetta, G., Camm, A.J., Goto, S., Kayani, G., Misselwitz, F., Turpie, A.G.G., Kakkar, A.K.

Get full text

P2895Evaluation of the effect of oral anticoagulants on all-cause mortality within 3 months of the diagnosis of atrial fibrillation: results from the GARFIELD-AF prospective regist... by Fox, K A A, Berchuck, S, Camm, A J, Bassand, J.-P, Fitzmaurice, D A, Gersh, B J, Goldhaber, S Z, Goto, S, Haas, S, Misselwitz, F, Pieper, K, Turpie, A G G, Verheugt, F W A, Kakkar, A K

Get full text